Trial · NCT06012734
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
NCT06012734, Phase 1, Recruiting, The Netherlands Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients. Trials, record NCT06012734. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06012734
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
- NCT number
- NCT06012734
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 37 participants, estimated
- Lead sponsor
- The Netherlands Cancer Institute
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- LB-100, Atezolizumab
- First posted
- 2023-08-25
- Last updated
- 2026-06-29
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The RP2D of LB-100 when given in combination with standard doses of atezolizumab | up to 2 years | |
| Secondary | Disease control rate | 6 months | Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| Secondary | Objective response rate | 6 months | Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| Secondary | Duration of overall response | up to 2 years | Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| Secondary | Progression free survival | up to 2 years | Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| Secondary | Overall survival | Assessed up to 2 years | The time from the first dose of study treatment to the time of death from any cause. Patients who are still alive at the time of analysis will be censored at the time of their last study assessment (for active patients) or at the last date know alive (for patients in follow-up). |
| Secondary | Observed plasma concentrations of LB-100, its active metabolite endothall and atezolizumab | Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days | Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured |
| Secondary | Area under the plasma-time concentration curve of LB-100, its active metabolite endothall and atezolizumab | Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days | Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured |
| Secondary | Elimination half-life of LB-100, its active metabolite endothall and atezolizumab | Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days | Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured |
| Secondary | Total body clearance of LB-100, its active metabolite endothall and atezolizumab | Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days | Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06012734
GET https://conductscience.org/api/trials/v1/NCT06012734/registered